Method for monitoring early treatment response

Details Method for monitoring early treatment response Method for monitoring early treatment response

2007-10-30

2007-10-30

Casler, Brian L. (Department: 3737)

Surgery

Diagnostic testing

Detecting nuclear, electromagnetic, or ultrasonic radiation

C424S009300

Reexamination Certificate

active

10946741

ABSTRACT:
Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the cancerous tissue before and after treatment; the treatment comprises administration of a cell surface receptor inhibitor, for example, an EGFR inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of a cell surface receptor inhibitor in the treatment of cancer.

REFERENCES:
patent: 4354499 (1982-10-01), Damadian
patent: 4411270 (1983-10-01), Damadian
patent: RE32619 (1988-03-01), Damadian
patent: RE32689 (1988-06-01), Damadian
patent: 4843321 (1989-06-01), Sotak
patent: 4962357 (1990-10-01), Sotak
patent: 5111819 (1992-05-01), Hurd
patent: 5200345 (1993-04-01), Young
patent: 5578921 (1996-11-01), Morrell
patent: 5585118 (1996-12-01), Stoll
patent: 5617861 (1997-04-01), Ross et al.
patent: 5887588 (1999-03-01), Usenius et al.
patent: 5903149 (1999-05-01), Gonen et al.
patent: 6046589 (2000-04-01), Lamerichs et al.
patent: 6181134 (2001-01-01), Wald
patent: 6280383 (2001-08-01), Damadian
patent: 6347239 (2002-02-01), Arnold et al.
patent: 6400150 (2002-06-01), Liu et al.
patent: 6617169 (2003-09-01), Ke et al.
patent: 6630125 (2003-10-01), DeGrado et al.
patent: 6639405 (2003-10-01), Liu et al.
patent: 6681132 (2004-01-01), Katz et al.
patent: 6708053 (2004-03-01), Brooks et al.
patent: 6756063 (2004-06-01), Kiss
patent: 2001/0003423 (2001-06-01), Wald
patent: 2002/0142367 (2002-10-01), Ke et al.
patent: 2002/0173713 (2002-11-01), Pfefferbaum et al.
patent: 2003/0028093 (2003-02-01), Ke et al.
patent: 2003/0199751 (2003-10-01), Gonzalez et al.
patent: 2003/0208120 (2003-11-01), Thomas et al.
patent: 2003/0214292 (2003-11-01), Heid et al.
patent: 2004/0092809 (2004-05-01), DeCharms
patent: 2005/0107683 (2005-05-01), Mountford et al.
patent: 2006/0035945 (2006-02-01), Attardo et al.
patent: 2006/0177377 (2006-08-01), Norfray
patent: 2006/0177378 (2006-08-01), Norfray
Negendank, “Studies of Human Tumors by MRS: a Review,” NMR In Biomedicine, vol. 5, pp. 303-324 (1992).
Harrigan, “Angiogenic Factors in the Central Nervous System,” Neurosurgery, vol. 53, No. 3, pp. 639-660 (2003).
Negendank, “Proceedings of a National Cancer Institute Workshop: MR Spectroscopy and Tumor Cell Biology,” Radiology, vol. 185, pp. 875-883 (1992).
Evelhoch, “Response-specific Adriamycin Sensitivity Markers Provided in in Vivo31P Nuclear Magnetic Resonance Spectroscopy in Murine Mammary Adenocarcinomas1,” Cancer Research, vol. 47, pp. 3396-3401 (1987).
Ruiz-Cabello, “Phospholipid Metabolites as Indicators of Cancer Cell Function,” NMR in Biomedicine, vol. 5, pp. 226-233 (1992).
Ross, “The Biochemistry of Living Tissues: Examination by MRS,” (1992).
Ross et al., “Metabolic Response of Glioblastoma to Adoptive Immunotherapy: Detection by Phosphorus MR Spectroscopy,” Journal of Computer Assisted Tomography, vol. 13, No. 2, pp. 189-193, (1989).
Norfray et al., “Clinical Impact of MR Spectroscopy When MR Imaging Is Indeterminate for Pediatric Brian Tumors,” AJR, vol. 173, pp. 119-125, (1999).
Norfray et al., “Alzheimer's Disease: Neuropathologic Findings and Recent Advances in Imaging,” AJR, vol. 182, No. 3, pp. 3-13, (2004).
Ross et al,, “Osteosarcoma and Other Neoplasms of Bone,” Arch Surg., vol. 122, pp. 1464-1469, (1987).
Griffiths et al., “31P-NMR Studies of a Human Tumour in Situ,” The Lancet, pp. 1435-1436, (1983).
Norfray et al., “Short TE Proton MRS and Neurofibromatosis Type 1 Intracranial Lesions,” Journal of Computer Assisted Tomography, vol. 23, No. 6, pp. 994-1003 (1999).
Norfray, et al., “Magnetic Resonance Spectroscopy,” in Pediatric Neurosurgery, 4thEdition, McLone (ed), pp. 1189-1203 (2001).
Ross et al., “Monitoring Response to Chemotherapy of Intact Human Tumours by31P Nuclear Magnetic Resonance,” The Lancet, pp. 641-646 (1984).
Norfray et al., “Monitoring Treatment Response with Choline Molecular Imaging,” ARRS Annual Meeting, May 4-9, 2003. 1 page Abstract.
Schwarz et al., “Early in vivo Detection of Metabolic Response: A Pilot Study of1H MR Spectroscopy in Extracranial Lymphoma and Germ Cell Tumours,” The British Journal of Radiology, pp. 959-966 (2002).
Erlich, “Cancer Drug Development: New Directions and Challenges—Smi Conference,” Idrugs, vol. 6, No. 4, pp. 331-333 (2003).
Eliason et al., “Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients,” Current Drug Targets, vol. 5, pp. 383-388 (2004).
Matsumoto et al., “Bax to Bcl-2 Ratio and Ki-67 Index are Useful Predictors of Neoadjuvant Chemoradiation Therapy in Bladder Cancer,” Jpn. J. Clin. Oncol, vol. 34, No. 3, pp. 124-130 (2004).
Fujimoto et al., A new immunological parameter predicting the efficacy of cancer therapy, Editorial, Annals of Cancer Research and Therapy, vol. 7, No. 2 (Title Only).
Fujimoto et al., Involvement of Tumor-specific CD4 and CD8 Suppressor T Cell (Ts) Lines in Down-regulation of Anti-tumor Immunity to a Murine Syngeneic Sarcoma, The 11thInternational Congress of Immunology 2001 (Abstract).
Abstract, AR Bianco et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, M. Boyer, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, F. Cappuzzo et al. I, British Journal of Cancer, vol. 89, (Supp. 2) (2003). S25-S35.
Abstract, F. Cappuzzo et al. II, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, F de Braud et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract J de la Cruz et al. I, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, J de la Cruz et al. II British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, K de Leeuw et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, E. Diaz-Canton, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, DM Kowalski et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, P. Maione et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, A. Mancuso et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Absract, S. Martin-Algarra et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, JL Martinez, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, E. Razis et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, M. Reck et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, BN Stein et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, R van der Kamp et al., British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, N. van Zandwijk I, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, N. van Zandwijk II, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Abstract, MD Vincent, British Journal of Cancer, vol. 89, (Suppl. 2) (2003). S25-S35.
Blackledge, G. et al., “Gefitnib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors,” British Journal of Cancer (2004) 90, 566-572.
Ranson, M. et al., “ZD1839, a Selective Oral Epidermal . . . Results of a Phase I Trial,” Journal of Clinical Oncology, vol. 20, No. 9 (May 1, 2002: pp. 2240-2250).
Katz, A. et al., “Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib,” British Jou

Affiliated with

Also associated with

Rating

Method for monitoring early treatment response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for monitoring early treatment response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for monitoring early treatment response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3826654